Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eosinophil-driven corticotherapy for hospitalized COPD exacerbation
2019-002724-33Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prednisone in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Treatment failure at 3 months. Started Sep 2019; status: completed.
02
Drugs
prednisone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2019-002724-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002724-33.